Table 1.

Patient demographic and preoperative characteristics.

Variable	Alemtuzumab	Basiliximab	p value	Odds Ratio	95% CI
	n = 453	n = 354
Age, Median (IQR)	60.23 (50.08 - 66.49)	60.16 (50.03 - 66.02)	0.58	-	-
Age 70 or older	39 (8.9)	37 (10.7)	0.42	1.22	0.76-1.95
Sex
Female	201 (44.4)	144 (40.7)	0.29	1.16	0.88-1.54
Male	252 (55.6)	210 (59.3)
Diagnosis
COPD/Emphysema/BO	153 (33.8)	102 (28.8)	0.002	-	-
Pulmonary Fibrosis	162 (35.8)*	152 (42.9)*
Suppurative	57 (12.6)	59 (16.7)
Scleroderma	54 (11.9)*	19 (5.4)*
Pulmonary Hypertension	9 (2.0)	10 (2.8)
Occupational	15 (3.3)	6 (1.7)
Other	3 (0.7)	6 (1.7)
Lung allocation score, Median (IQR)	43.6 (34.6 - 66.6)	46.8 (36.1-67.9)	0.07	-	-
Body mass index, Median (IQR)	25.6 (21.4 - 29.3)	24.6 (20.9-28.7)	0.07	-	-
Waiting list time (days), Median (IQR)	50.0 (16.0 - 143.0)	46.5 (19.0-180.3)	0.29	-	-
Recipient CMV positive	267 (58.9)	104 (29.4)	< 0.001	0.29	0.22-0.39
Recipient EBV positive	436 (97.5)	334 (95.7)	0.15	0.56	0.26-1.24
HCV history	6 (1.3)	18 (5.1)	0.002	3.99	1.57-10.16
HIV history	0 (0.0)	6 (1.7)	0.005	0.43	0.40-0.47
CMV Mismatch	43 (9.5)	213 (60.2)	< 0.001	14.4	9.86-21.05
EBV Mismatch	10 (2.2)	14 (4.0)	0.15	1.82	0.80-4.16
Preoperative steroids	195 (43.0)	152 (42.9)	0.98	1	0.75-1.32
Preoperative hepatic disease	9 (2.0)	20 (5.6)	0.006	2.94	1.32-6.54
Oncology history	13 (2.9)	82 (23.2)	< 0.001	10.2	5.58-18.67
ECMO Bridge	36 (8.0)	34 (9.6)	0.41	1.23	0.75-2.01

^*p < 0.05 post hoc. IQR, Interquartile range; COPD, Chronic obstructive pulmonary disease; BO, Bronchiolitis obliterans.